Health Ministry Helps Financing Clinical Trial of Terawan's Nusantara Vaccine
Translator
Editor
19 February 2021 15:57 WIB
TEMPO.CO, Jakarta - The Health Ministry confirmed that it had also took part in financing the clinical trials of Nusantara Vaccine that was developed by former Health Minister Terawan Agus Putranto in collaboration with the research team from the Laboratory of Semarang Kariadi Hospital in Central Java, the United States' Aivita Biomedical Corporation, and Diponegoro University.
"Yes, we are funding the phase-1 clinical trial," said Slamet, the Head of the ministry's Research and Development Agency, in an online discussion event on Friday, February 19, 2021.
However, Slamet stopped short of detailing the amount of funds disbursed for the research on the vaccine against the coronavirus infection. Slamet emphasized that financial assistance was provided as a form of support for efforts in suppressing the virus spread.
Meanwhile, The Food and Drug Monitoring Agency (BPOM) Head Penny K. Lukito, said that BPOM is currently evaluating the data from the phase-1 clinical trial results submitted by the team a few days ago.
The Health Ministry could not yet confirm whether the vaccine would be used in Indonesia as it required a recommendation from the Indonesian Technical Advisory Group on Immunization (ITAGI).
To date, the Indonesian government has determined seven brands of Covid-19 vaccine used in the country, such as Bio Farma, AstraZeneca, Sinopharm, Moderna, Novavax Inc, Pfizer Inc and BioNtech, and Sinovac Biotech.
Also Read: BPOM Comments on Candidate Vaccine by Former Health Minister Terawan
DEWI NURITA